## **ABSTRACT**

The present invention provides compounds of Formula (I):

$$X^{2}$$

$$X^{1}$$

$$X^{2}$$

$$X^{3}$$

$$X^{4}$$

$$X^{16}$$

$$X^{15}$$

$$X^{15}$$

$$X^{16}$$

$$X^{15}$$

$$X^{15}$$

$$X^{16}$$

$$X^{15}$$

$$X^{16}$$

or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein the

variables A, B, L<sub>1</sub>, L<sub>2</sub>, X<sup>1</sup>, X<sup>2</sup>, X<sup>3</sup>, X<sup>4</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup> and R<sup>16</sup> are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.